BioCentury
ARTICLE | Financial News

Idec misses, GENZ tops consensus EPS

April 20, 2000 7:00 AM UTC

IDPH reported first quarter EPS of $0.07, $0.05 lower than the Street estimate. Although the numbers had been expected since partner Genentech (DNA) released its earnings last week, IDPH was down $14.25 to $63.125 on Thursday. Since last Wednesday's announcement, IDPH is off 29 percent. IDPH's portion of sales of its Rituxan rituximab antibody to treat non-Hodgkin's lymphoma came in at $78 million, compared to $52 million in the first quarter of 1999. The product is co-promoted in the U.S. with DNA (see BioCentury Extra, April 12). ...